Immune checkpoint blockade (ICB) has undoubtedly changed the landscape of cancer therapies, with PD-1, CTLA-4, and PD-1/LAG-3 therapies becoming FDA-approved for use in multiple malignancies, leading to improved survival for many patients [174,175]. The gene discussed is LAG3; the disease is cancer.